

The role and fate of rabbit and human transcobalamin II in the plasma transport of vitamin B12 in the rabbit.

R J Schneider, ... , C S Mehlman, R H Allen

J Clin Invest. 1976;57(1):27-38. <https://doi.org/10.1172/JCI108265>.

Research Article

Previous studies have shown that plasma transcobalamin II (TCII) facilitates the cellular uptake of [57Co] vitamin B12 (B12) by a variety of tissues, but the lack of an intrinsic label on the protein moiety of the TCII-B12 complex has made it impossible to determine the role and fate of TCII during this process. We have labeled homogenous rabbit and human TCII with 125I-labeled N-succinimidyl-3-(4-hydroxyphenyl) propionate and have performed in vivo experiments in rabbits. When 125I-labeled rabbit TCII-[57Co] B12 and 131I-labeled bovine albumin were simultaneously injected intravenously, we observed that 125I and 57Co were cleared from plasma at a faster rate ($t_{1/2} = 1 \frac{1}{2}$ h) than 131I and that 125I and 57Co were present in excess of 131I in the kidney, liver, spleen, heart, lung, and small intestine 1/2 h after injection. Later, 57Co remained in excess of 131I, but the ratio of 125I to 131I decreased progressively in all of these plasma and were rapidly excreted in the urine. After 1 h following injection, 57Co was present in excess of 125I in the plasma...

Find the latest version:

<https://jci.me/108265/pdf>



The Role and Fate of Rabbit and Human Transcobalamin II in the Plasma Transport of Vitamin B₁₂ in the Rabbit

ROBERT J. SCHNEIDER, ROBERT L. BURGER, CAROL S. MEHLMAN, and
ROBERT H. ALLEN

*From the Divisions of Hematology and Oncology, Department of Internal
Medicine, Washington University School of Medicine,
St. Louis, Missouri 63110*

ABSTRACT Previous studies have shown that plasma transcobalamin II (TCII) facilitates the cellular uptake of [⁵⁷Co]vitamin B₁₂ (B₁₂) by a variety of tissues, but the lack of an intrinsic label on the protein moiety of the TCII-B₁₂ complex has made it impossible to determine the role and fate of TCII during this process. We have labeled homogeneous rabbit and human TCII with ¹²⁵I-labeled *N*-succinimidyl-3-(4-hydroxyphenyl) propionate and have performed *in vivo* experiments in rabbits.

When ¹²⁵I-labeled rabbit TCII-[⁵⁷Co]B₁₂ and ¹²⁵I-labeled bovine albumin were simultaneously injected intravenously, we observed that ¹²⁵I and ⁵⁷Co were cleared from plasma at a faster rate (*t*₁ = 1½ h) than ¹²⁵I and that ¹²⁵I and ⁵⁷Co were present in excess of ¹²⁵I in the kidney, liver, spleen, heart, lung, and small intestine ½ h after injection. Later, ⁵⁷Co remained in excess of ¹²⁵I, but the ratio of ¹²⁵I to ¹²⁵I decreased progressively in all of these tissues; ¹²⁵I fragments (mol wt less than 1,000) appeared in the plasma and were rapidly excreted in the urine. After 1 h following injection, ⁵⁷Co was present in excess of ¹²⁵I in the plasma. Additional experiments revealed that both isotopic moieties of human TCII-B₁₂ were cleared from rabbit plasma 30% faster than their rabbit TCII-B₁₂ counterparts and that apo-rabbit TCII and apo-human TCII were cleared from rabbit plasma 30% faster than holo-rabbit TCII and holo-human TCII, respectively.

These studies, and appropriate control experiments, indicate that TCII and the TCII-B₁₂ complex are cleared

This work was presented in part at the Annual Meeting of the American Society of Hematology, Atlanta, Ga., 9 December 1974. A preliminary report has appeared in abstract form (1).

Dr. Allen is the recipient of Faculty Research Award (FRA 122) from the American Cancer Society.

Received for publication 14 March 1975 and in revised form 5 September 1975.

from plasma by a variety of tissues, that the TCII moiety is degraded during this process, and that a significant portion of the B₁₂ recirculates.

INTRODUCTION

Human plasma contains three vitamin B₁₂ (B₁₂)¹-binding proteins, referred to (2-6) as transcobalamin I (TCI), transcobalamin II (TCII), and transcobalamin III (TCIII). TCI and TCIII are glycoproteins and belong to the group of immunologically similar proteins known as the R-type B₁₂-binding proteins (6-10). Approximately 70-90% of the endogenous B₁₂ in human plasma is bound to TCI (6, 11), but [⁵⁷Co]B₁₂ bound to TCI is cleared slowly from human plasma with a *t*₁ of 9-12 days (12). TCIII is derived from granulocytes (2, 6), contains less sialic acid than TCI (6), and appears to circulate *in vivo* at a barely detectable level, less than 30% that of TCI (2, 6). Both moieties of ¹²⁵I-labeled human TCIII-[⁵⁷Co]B₁₂ are cleared rapidly (*t*₁ < 5 min) from rabbit plasma by the liver (13) by the mechanism described by Ashwell and Morell (14) for the clearance and catabolism of a wide variety of asialoglycoproteins. This observation suggests that TCIII might serve a scavenger function for B₁₂ released into areas of cell necrosis or infection. This function is compatible with the lack of any hematologic abnormalities in two brothers with apparent congenital deficiencies of all R-type B₁₂-binding proteins (15).

TCII is not a glycoprotein (5) and is immunologically distinct from the R-type proteins (4). TCII facilitates the cellular uptake of [⁵⁷Co]B₁₂ by a variety of cells *in vitro* (16-20), and a congenital deficiency of this protein results in a severe megaloblastic anemia that re-

¹ Abbreviations used in this paper: B₁₂, vitamin B₁₂; TCI, transcobalamin I; TCII, transcobalamin II; TCIII, transcobalamin III.

sponds only to large frequent injections of B_{12} (21). TCII contains only 10-20% (6, 11) of the endogenous B_{12} in human plasma, but approximately 70% of [^{57}Co] B_{12} bound to human TCII is cleared from human plasma in the 10 min after injection (12). During the following hours, t_1 values for clearance have been estimated in the range of 1 h (22) to 12 h (12). The lack of a label on the protein moiety of TCII- B_{12} has made it impossible to determine whether the early rapid plasma clearance of [^{57}Co] B_{12} is due to an unusually large extracellular fluid distribution of TCII- B_{12} or whether the slow, late clearance of [^{57}Co] B_{12} is due to recirculation of the [^{57}Co] B_{12} molecule. To elucidate the role and fate of TCII in the plasma transport of B_{12} , we have labeled rabbit and human TCII with ^{125}I and have studied the plasma clearances of these proteins in the presence and absence of [^{57}Co] B_{12} in rabbits.

METHODS

Protein preparations. Human TCII was isolated from Cohn fraction III of normal human plasma, as described previously (5), except that the preparation employed here was isolated from a different batch of Cohn fraction III. When a 20 μg of this second preparation of human TCII was subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis in the presence of 1% 2-mercaptoethanol, a single protein band was observed, with an apparent mol wt of 38,000. This differs from the original preparation, which gave two protein bands with apparent mol wts of 38,000 and 25,000 (5). The significance of this difference will be discussed elsewhere.² The two preparations were otherwise identical in terms of amino acid composition, amino acid content relative to B_{12} , lack of carbohydrate, absorption spectra, apparent mol wt (38,000) based on gel filtration at low TCII concentrations (< 10 $\mu\text{g}/\text{ml}$), yield (15%), and overall purification (2,000,000-fold relative to plasma).

Rabbit TCII was isolated from 20 liters of rabbit serum (type 2 from 1-3-yr-old rabbits, Pel-Freez Bio-Animals, Inc., Rogers, Ark.) by a purification scheme consisting of affinity chromatography on B_{12} -Sepharose, chromatography on DEAE-cellulose, and gel filtration on Sephadex G-150. These purification techniques were performed essentially as described for human TCII (5), and details will be presented elsewhere.² The final preparation was purified 40,000-fold relative to serum, with a yield of 31%, and gave a single band on sodium dodecyl sulfate polyacrylamide gel electrophoresis with an apparent mol wt of 40,000. Purified rabbit TCII gave a single precipitin line on immunodiffusion against chicken anti-human TCII with a pattern of partial identity to human TCII.

Labeling of proteins with ^{125}I and ^{131}I . *N*-Succinimidyl 3-(4-hydroxyphenyl) propionate (Pierce Chemical Co., Rockford, Ill.) was labeled with ^{125}I and ^{131}I (carrier-free, 50-200 mCi/ml, Mallinckrodt Chemical Works, St. Louis, Mo.) by a modification of the method of Bolton and Hunter (23). The following components were added sequentially at 5-10-s intervals at room temperature to a test tube that contained 2.5 μg of dry *N*-succinimidyl 3-(4-hydroxyphenyl) propionate: (a) 9.6 mCi of Na^{125}I in 150 μl of H_2O ; (b) 250 μg

² Allen, R. H., R. J. Schneider, R. L. Burger, and C. S. Mehlman. Manuscript in preparation.

of chloramine T in 50 μl of 0.25 M potassium phosphate, pH 7.5; (c) 600 μg of sodium metabisulfite in 50 μl of 0.05 M potassium phosphate, pH 7.5, (d) 1 mg of KI in 50 μl of 0.05 M potassium phosphate, pH 7.5; and (e) 25 μl of dimethylformamide. The solution was extracted rapidly with two 0.5-ml portions of benzene. The benzene extracts were combined, divided into aliquots, and dried by a stream of nitrogen. Approximately 0.21 mol of ^{125}I were coupled per mol of ester, if all of the ester and none of the free ^{125}I was recovered in the benzene extract.

Rabbit TCII (approximately 25 μg of protein saturated with 0.75 μg of bound B_{12}) in 75 μl of 0.1 M boric acid-KOH, pH 8.5, 0.75 M NaCl, was added to 0.75 μg of the dried, ^{125}I -labeled ester, and the reaction mixture was gently agitated at 4°C. After 15 min, 200 μl of 0.2 M glycine in 0.1 M boric acid-KOH, pH 8.5, was added, before an additional 5 min of agitation. Gelatin (type I, Sigma Chemical Co., Inc., St. Louis, Mo.), 2.5 mg in 1.0 ml of 0.05 M potassium phosphate, pH 7.5, 0.75 M NaCl was added to reduce the adsorption of ^{125}I -labeled rabbit TCII to dialysis tubing, and the sample was dialyzed for 24 h at 4°C against 1.2 liters of 0.05 M potassium phosphate, pH 7.5, 0.75 M NaCl, with a dialysate change after 19 h. Human TCII (approximately 16 μg of protein saturated with 0.50 μg of bound B_{12}) was incubated with 0.5 μg of the same preparation of ^{125}I -labeled ester in a volume of 50 μl . ^{131}I -labeled ester was prepared as described above for the ^{125}I -labeled ester. Approximately 0.20 mol of ^{131}I was coupled per mol of ester. Rabbit TCII and human TCII were labeled with ^{131}I -labeled ester as described above for ^{125}I . Bovine serum albumin (type V, Sigma Chemical Co.), 5 μg , was incubated with 0.25 μg of ^{131}I -labeled ester in a volume of 10 μl .

Removal and replacement of B_{12} . The low-specific-activity [^{57}Co] B_{12} (< 0.03 $\mu\text{Ci}/\mu\text{g}$), bound to ^{125}I and ^{131}I -labeled rabbit and human TCII, was removed (> 99%) by dialysis of the entire sample at room temperature for 72 h against 15 vol of 0.1 M potassium phosphate, pH 7.5, containing 7.5 M guanidine-HCl, with dialysate changes after 24 and 48 h. A twofold excess of high-specific-activity [^{57}Co] B_{12} (15 $\mu\text{Ci}/\mu\text{g}$) was added to aliquots of the dialyzed protein samples, and each sample was adjusted to contain 5.0 M guanidine-HCl in a volume of 1.5 ml. The samples were then dialyzed against 550 ml of 0.01 M potassium phosphate, pH 7.5, containing 0.14 M NaCl for 16 h at 4°C. Thereafter, samples were adjusted to contain 0.25 mg bovine serum albumin, 0.05 M potassium phosphate, pH 7.5, and 0.75 M NaCl in a volume of 2.5 ml and were applied to a column (2.0 cm diameter by 60 cm in height) of Sephadex G-150 equilibrated at 4°C with 0.05 M potassium phosphate, pH 7.5 and 0.75 M NaCl. Fractions of 3.0 ml were collected in glass test tubes that contained 300 μg of bovine serum albumin in 150 μl of equilibrating solution. The bovine serum albumin served to reduce the adsorption of ^{125}I - and ^{131}I -labeled proteins to glass. Appropriate fractions (see "Results") were pooled and stored in 5-ml aliquots at -20°. ^{131}I -labeled rabbit and human TCII devoid of B_{12} were prepared as just described, except that [^{57}Co] B_{12} was not added before the final dialysis step.

Experiments employing rabbits. Male New Zealand White rabbits, 1.9-2.9 kg, (Ernest Elridge Rabbitry, St. Louis, Mo.) were fasted for 16 h before being used for experiments. Rabbits were restrained, and a continuous infusion (0.2-0.8 ml/min) of sterile 0.9% NaCl was begun through a butterfly-short-25-pediatric infusion set (Abbott Laboratories, North Chicago, Ill.) inserted in the lateral ear vein and connected to a three-way stopcock. Rabbits were sedated by a single intravenous injection of pentobarbital

(25 mg/kg body wt). In experiments involving nephrectomy or ureteral ligation, the dose was increased by 50–100%, and additional amounts were given as required to maintain sedation. The bladder was catheterized with a number 8 French Foley pediatric catheter (The Kendall Co., Consumer Products Div., Chicago, Ill.). Radioactive protein samples (2–4 ml in 0.05 M potassium phosphate, pH 7.5, 0.75 M NaCl) were mixed together in a counting vial (Poly Q vial, Beckman Instrument Co., Schiller Park, Ill.), taken up in a syringe, and injected intravenously through the three-way stopcock at time zero. Blood samples were obtained by puncture with a number 20 needle of the median artery of the ear not used for the infusion. Blood samples (2–5 ml) were collected in 5-ml Vacutainer tubes (Becton, Dickinson & Co., Rutherford, N. J.) containing 7.2 mg of K_2EDTA and 0.01 mg of potassium sorbate in 48 μ l of H_2O . Plasma was collected by centrifugation at 4,000 g for 10 min at 4°C. There was no significant uptake or adsorption of any of the radioactive items by either blood cells or test tubes. Urine was collected at intervals by syringe aspirations of the bladder catheter. The bladder was rinsed with two 15-ml vol of 0.9% NaCl during each collection. Rabbits were killed by the rapid intravenous injection of 3 ml of 0.9% NaCl that contained 300 mg of pentobarbital. Death occurred within 15 s. Organs were removed within 20 min after death and were rinsed lightly before being assayed for radioactivity.

Measurements of radioactivity. ^{125}I , ^{131}I , ^{57}Co , and ^{58}Co were assayed with a Beckman G-300 three-channel gamma spectrometer (Beckman Instruments Inc., Fullerton, Calif.). Corrections were made for variations in counting efficiency, isotope spillover, and isotope decay. Spillover accounted for less than 10% of the total radioactivity measured for any particular isotope in any of the samples assayed. The amount of each isotope injected into a rabbit was calculated from the total volume of the sample and the measured concentration of the isotope. This value was corrected for the amount of each isotope that remained in the syringe and counting vial, as determined by direct assay of these items.

All samples were counted in the same type of plastic counting vials. This was important since the counting efficiency of ^{125}I varied by as much as 50% when the same sample was counted in various types of counting vials. Variations in counting efficiency were not noted with ^{57}Co , ^{58}Co , or ^{131}I . Variation in the counting efficiency for ^{125}I was also noted with samples from different tissues, based on experiments in which ^{125}I -labeled bovine serum albumin and ^{131}I -labeled bovine serum albumin were simultaneously injected intravenously into rabbits. At 25 min after injection, the ratio of ^{131}I to ^{125}I in the plasma was within 1% of the preinjection ratio, but the ratio varied in various organs as follows: kidney, 1.31; liver, 1.15; spleen, 1.09; heart, 1.07; lung, 1.07; and small intestine, 1.09. These ratios varied by less than 3% in three rabbits that were studied. These ratios were used to correct the amount of ^{125}I present in individual tissues in experiments in which other ^{125}I -labeled proteins were studied.

Radioimmunoassay of human TCII. Test tubes contained the following: (a) 250 μ l of rabbit plasma, consisting of varying amounts of control plasma and control plasma containing human TCII- B_{12} (0.25 μ g protein saturated with 8 ng of bound B_{12} /ml of plasma); (b) 200 μ l of 0.1 M potassium phosphate, pH 7.5, 1.5 M NaCl; (c) 25 μ l of 0.05 M potassium phosphate, pH 7.5, 0.75 M NaCl containing ^{125}I -labeled human TCII- B_{12} (1 ng of protein, 33 pg B_{12}), and 40 μ g of bovine serum albumin; and (d) 25 μ l of 0.05

M potassium phosphate, pH 7.5, 0.75 M NaCl, containing 0.3 μ l of rabbit anti-human TCII serum. After 17 h of gentle agitation at 4°C, 500 μ l of 0.05 M potassium phosphate, pH 7.5, 0.75 M NaCl, containing 71 mg of polyethylene glycol (mol wt = 6000, Union Carbide Corp., New York) was added. After standing for 15 min, the tubes were centrifuged at 6,000 g for 15 min, and 500 μ l of the supernatant liquid was assayed for ^{125}I . Under these conditions, 60% of the ^{125}I -labeled human TCII- B_{12} precipitated in the absence of unlabeled human TCII- B_{12} . This value fell significantly and progressively to 10% as the amount of unlabeled human TCII- B_{12} was increased over the range from 2 to 60 ng of protein. Additional details, including the observation that immunoreactive TCII is absent from the plasma of two patients with congenital TCII deficiency, will be presented elsewhere.³

Other methods. Gel filtration on Sephadex G-150 (24), B_{12} -binding assays (24), B_{12} assays (6), sodium dodecyl sulfate polyacrylamide gel electrophoresis (24), immunization of animals (8), immunodiffusion (8), immunoprecipitation assays (9), and the preparation of B_{12} -Sepharose (25) were performed as described previously.

RESULTS

Gel filtration profile of pooled rabbit serum. When pooled rabbit serum was subjected to gel filtration on Sephadex G-150, the endogenous B_{12} and B_{12} -binding ability eluted as shown in Fig. 1A. Over 95% of the B_{12} -binding ability eluted in a single peak with an apparent mol wt of 40,000 and represents rabbit TCII, since more than 90% of a saturating amount of [^{57}Co]- B_{12} bound to material in this region was precipitated by chicken anti-human TCII serum. Approximately 80% of the endogenous B_{12} eluted in the position of rabbit TCII, while approximately 20% eluted with an apparent mol wt of 145,000. The nature of the latter material has not been determined, although it may represent rabbit R-type protein. The elution profiles obtained for rabbit serum differ from those obtained for human serum, since human serum contains only 2% as much B_{12} and B_{12} -binding ability as rabbit serum, and only 10–20% of the total B_{12} is bound to human TCII (6, 11).

Properties of ^{125}I and ^{131}I -labeled proteins. When ^{125}I -labeled rabbit TCII was saturated with [^{57}Co] B_{12} and applied to a column of Sephadex G-150, the elution profiles presented in Fig. 1B were obtained. More than 90% of the [^{57}Co] B_{12} eluted in a symmetrical peak with an apparent mol wt of 40,000. The majority of the ^{125}I was present in the same region, although a significant amount was spread out from the void volume of the column to the 40,000 apparent mol wt region. The nature of the dispersed ^{125}I -labeled material has not been determined, although it may result from alteration of the protein during the ^{125}I -labeling procedure or during the guanidine denaturation and renaturation procedure.

³ Mehlman, C. S., C. R. Scott, and R. H. Allen. Manuscript in preparation.




FIGURE 1 Gel filtration of rabbit serum and ^{125}I -labeled rabbit TCII- ^{57}Co B₁₂. Samples of 6 ml, containing 2 mg of blue dextran, were applied to a column (55 cm in height by 2.0 cm in diameter) of Sephadex G-150 equilibrated at 4°C with 0.05 M potassium phosphate, pH 7.5, containing 0.75 M NaCl. Fractions of 3.0 ml were collected in tubes containing 300 μg of bovine serum albumin in 150 μl of equilibration solution. The void volume of the column at fraction 21 was as indicated by the arrows. The numbers in parentheses indicate apparent molecular weight values, estimated from the elution positions of proteins of known molecular weight. The samples contained: (A) 5.8 ml of pooled rabbit serum containing a total of 174 ng of endogenous B₁₂ and 80 ng of B₁₂-binding ability. (B) Initial preparation of ^{125}I -labeled rabbit TCII- ^{57}Co B₁₂ containing 120 ng of ^{57}Co B₁₂ and prepared as described under Methods. The horizontal bar indicates the positions of fractions 32–36, which were pooled. (C) 2.0 ml of pooled fractions 32–36 from B. (D) Rabbit plasma (6.0 ml) obtained from a nephrectomized rabbit 240 min after the intravenous injection of 2.0 ml of pooled fractions 32–36 from B. Values from C and D were corrected for isotope decay and variation in counting efficiency, and correspond to the values in B.

This same phenomenon was observed with ^{125}I -labeled human TCII- ^{57}Co B₁₂ and with ^{125}I -labeled rabbit and human TCII devoid of B₁₂ (data not presented).

The ^{125}I -labeled rabbit TCII- ^{57}Co B₁₂ in pooled fractions 32–36 from Fig. 1B was utilized for in vivo experiments. Corresponding pooled fractions were utilized

for the other protein preparations. Fig. 1C portrays the elution profiles obtained when an aliquot of the final preparation of ^{125}I -labeled rabbit TCII- ^{57}Co B₁₂ was subjected to repeat gel filtration on Sephadex G-150. Approximately 2% of the ^{125}I was still present in the void volume, and a corresponding amount of ^{57}Co B₁₂ was present as free ^{57}Co B₁₂. Both of these components increase slowly during the storage of ^{125}I -labeled rabbit TCII- ^{57}Co B₁₂ at a rate of approximately 2% of the total per week. The ^{125}I in the void volume was not precipitated by chicken anti-human TCII serum. This phenomenon was observed with the other protein preparations utilized for in vivo experiments. All of the experiments presented here were performed within 3 wk of the labeling of these proteins.

More than 90% of both moieties of the final preparation of ^{125}I -labeled rabbit TCII- ^{57}Co B₁₂ were precipitated by chicken anti-human TCII serum. Less than 10% of either moiety was precipitated by rabbit anti-human TCII serum, or was absorbed by B₁₂-Sephadex. ^{125}I -labeled human TCII- ^{57}Co B₁₂ behaved in the same manner except that more than 90% of both moieties were precipitated by rabbit anti-human TCII serum. The final preparations of ^{125}I -labeled rabbit and human TCII devoid of B₁₂ had the same precipitation characteristics as their ^{125}I -labeled TCII- ^{57}Co B₁₂ counterparts, but the ^{125}I -labeled TCII preparations were adsorbed (> 90%) by B₁₂-Sephadex. The molar ratios of ^{125}I to B₁₂ were 0.2 and 0.3 for the final preparations of ^{125}I -labeled rabbit TCII- ^{57}Co B₁₂ and ^{125}I -labeled human TCII- ^{57}Co B₁₂, respectively. The same values hold for the molar ratios of ^{125}I to protein, since TCII contains a single B₁₂-binding site (5). The molar ratios of ^{125}I to rabbit and human TCII devoid of B₁₂ were not significantly different from those observed with their ^{125}I -labeled TCII counterparts based on B₁₂ binding assays performed with the ^{125}I -labeled preparations.

Plasma survival of ^{125}I -labeled rabbit TCII- ^{57}Co B₁₂. When ^{125}I -labeled rabbit TCII- ^{57}Co B₁₂ and ^{125}I -labeled bovine serum albumin were simultaneously injected intravenously into a rabbit, the three isotopes were cleared from the plasma and excreted in the urine as shown in Fig. 2. The ^{125}I disappeared slowly from the plasma at a rate compatible with the equilibration of albumin with the extracellular fluid; 65% of the total amount of ^{125}I administered was present in the plasma 240 min after the injection. Approximately 5% of the ^{125}I was excreted in the urine during this time. Similar results were obtained with similarly labeled human transferrin in other experiments (data not presented). During the first 60 min after the injection, ^{57}Co and ^{125}I disappeared from the plasma at identical rates faster than that of ^{125}I . From 60 to 240 min, the plasma disappearance rate of ^{57}Co decreased, and 25% of the ^{57}Co remained in the plasma at the end of

this time. Less than 1% of the ^{67}Co was excreted in the urine during the 240 min period. After 60 min, the ^{125}I continued its initial rapid disappearance from the plasma, and only 15% remained after 240 min. After a delay of 30 min, large amounts of ^{125}I appeared in the urine; 42% of the administered amount had been excreted at the end of 240 min. The peak period of urinary excretion occurred at 60–100 min.

From the assumption that the difference between the plasma survival of ^{125}I and ^{125}I represents the tissue uptake of ^{125}I that is not attributable to diffusion into the extracellular fluid, a $t_{1/2}$ of approximately 90 min was estimated for this process. This value also holds for ^{67}Co during the initial 60 min after the injection of ^{125}I -labeled rabbit TCII- ^{67}Co B₁₂.

Properties of ^{125}I in the urine, and ^{125}I and ^{67}Co in the plasma after the intravenous injection of ^{125}I -labeled rabbit TCII- ^{67}Co B₁₂. When a sample of pooled urine obtained from the experiment shown in Fig. 2 was subjected to gel filtration on Sephadex G-150, all of the ^{125}I eluted in a single peak with an apparent mol wt of less than 1,000 (data not presented), suggesting that a significant portion of the ^{125}I -labeled rabbit TCII had been degraded during the experiment. Although the kidney is responsible for its excretion, at least a major part of this low-molecular-weight material must be formed by other tissues, since it was present in significant amounts in a 240-min plasma sample obtained from a rabbit nephrectomized 1 h before the injection of ^{125}I -labeled rabbit TCII- ^{67}Co B₁₂. The elution profile of this plasma sample is presented in Fig. 1D and reveals that essentially 100% of the ^{67}Co , but only 50% of the ^{125}I , eluted with an apparent mol wt of 40,000, the same as that of the starting material (seen Fig. 1C). More than 90% of the ^{125}I and ^{67}Co in this position were precipitated by chicken anti-human TCII serum; less than 10% were adsorbed by B₁₂-Sephadex. Approximately 40% and 10% of the plasma ^{125}I eluted with apparent mol wts of less than 1,000, and 70,000, respectively. None of the ^{125}I in either position was precipitated by chicken anti-human TCII serum or adsorbed by B₁₂-Sephadex. The nature of the ^{125}I in the less than 1,000 mol wt region has not been determined, although free ^{125}I and ^{125}I -labeled *N*-succinimidyl-3-(4-hydroxyphenyl) propionate, either free or attached to one or a few amino acids, are likely possibilities. The nature of the ^{125}I in the 70,000-mol-wt region is also unknown, although the ^{125}I appears to be covalently bound to some component, possibly rabbit albumin, since it was not dialysable when the plasma was dialyzed against 1% sodium dodecyl sulfate or 7.5 M guanidine-HCl containing 1% 2-mercaptoethanol. The fact that similar material has been observed (13) after the intravenous injections of ^{125}I -labeled human granulocyte B₁₂-binding protein and trans-




FIGURE 2 Plasma survival and urinary excretion of ^{125}I , ^{67}Co , and ^{131}I after the simultaneous intravenous injection of ^{125}I -labeled rabbit TCII- ^{67}Co B₁₂ and ^{131}I -labeled bovine serum albumin into a rabbit. The amount of each labeled protein injected was approximately 150 ng. The amount of B₁₂ injected was approximately 5 ng. The amount of ^{125}I present in the plasma 5 min after injection was assumed to be 100% of the injected amount and was used to calculate the plasma volume, assumed to remain constant throughout the experiment. A, plasma; B, cumulative urinary excretion.

cobalamin III suggests that it is formed after the catabolism of a number of similarly iodinated proteins.

Plasma samples obtained 5, 30, 60, 120, 180, 240, and 1,440 min after the simultaneous intravenous injection of ^{125}I -labeled rabbit TCII- ^{67}Co B₁₂ and ^{131}I -labeled bovine serum albumin into unneephrectomized rabbits were also studied by gel filtration. These studies revealed that the ratio of ^{125}I to ^{67}Co in the 40,000 apparent mol wt region was equal to the preinjection ratio in the 5- and 30-min samples and declined progressively in the 60- to 1,440-min. samples. All of the ^{67}Co in each sample was located in the apparent 40,000-mol-wt region. The low-mol-wt ^{125}I -material was not detectable in the 5- and 30-min plasma samples. It was present in greatest absolute and relative (10% of plasma ^{125}I) amount in the 60-min sample, and declined thereafter. The ^{125}I with an apparent mol wt of 70,000 was first detected in the 60-min sample, where it accounted for 1% of the total ^{125}I ; it slowly increased subsequently and accounted for 5% of the total ^{125}I in the 240-min sample. More than 90% of the ^{125}I in these samples eluted with an apparent mol wt of 70,000, the same as that of the ^{125}I -labeled bovine serum albumin in the starting sample.




FIGURE 3 Tissue distribution of ^{125}I , ^{57}Co , and ^{131}I at various time periods after the simultaneous injection of ^{125}I -labeled rabbit TCII- ^{57}Co B₁₂ and ^{131}I -labeled bovine serum albumin into rabbits. Experiments and calculations were performed as described in the legend to Fig. 2. The values for the 5- and 30-min time periods are average values obtained from five animals. The values for the other time periods were obtained from single animals. The entire small intestine, including its contents, was divided into three segments of equal length.

Tissue, rather than plasma or blood cells alone, appears to be required for the formation of the low-mol-wt ^{125}I -material, since when 5-min plasma and whole blood samples were incubated in vitro for 240 min at 37°C, with subsequent application of the plasmas to columns of Sephadex G-150, more than 95% of the ^{125}I and ^{57}Co -B₁₂ eluted in the 40,000-mol-wt position. Only approximately 10% of the ^{125}I was adsorbed by B₁₂-Sephadex,

thus indicating that significant dissociation of the complex had not occurred.

Tissue distribution of ^{125}I -labeled rabbit TCII- ^{57}Co -B₁₂. The tissue distributions of ^{125}I , ^{57}Co , and ^{131}I were determined at various times from 5 to 1,440 min after the simultaneous intravenous injection of ^{125}I -labeled rabbit TCII- ^{57}Co B₁₂ and ^{131}I -labeled bovine serum albumin into rabbits. The results are presented in Fig. 3

TABLE I
Relative Tissue Distribution of ^{125}I , ^{131}I , and ^{57}Co , 30 min after the Simultaneous Intravenous Injection of ^{125}I -Labeled Rabbit TCII- ^{57}Co B₁₂ and ^{131}I -Labeled Bovine Serum Albumin into Rabbits

Organ	$^{125}\text{I}/^{131}\text{I}$		$^{57}\text{Co}/^{131}\text{I}$		$^{125}\text{I}/^{57}\text{Co}$	
	Range	Mean	Range	Mean	Range	Mean
Plasma	0.70-0.80	0.76*	0.75-0.80	0.78*	0.94-1.02	0.98
Liver	1.10-1.49	1.29*	1.14-1.70	1.38*	0.90-1.00	0.95
Kidney	2.85-4.51	3.60*	2.97-4.57	3.58*	0.92-1.09	1.00
Spleen	1.15-1.65	1.37‡	1.11-1.80	1.44‡	0.88-1.11	0.98
Heart	1.17-1.46	1.31*	1.41-1.75	1.59*	0.77-0.88	0.83*
Lung	1.04-1.31	1.14‡	1.17-1.45	1.26*	0.88-0.93	0.90*
Small intestine						
Proximal	1.08-1.49	1.21‡	1.09-1.35	1.26*	0.98-1.12	1.04
Middle	1.23-1.30	1.27*	1.18-1.39	1.29*	0.91-1.05	0.98
Distal	1.16-1.37	1.24*	1.06-1.40	1.30*	0.86-1.10	0.96

Five rabbits were injected. Statistical analysis employed the Student *t* test and was based on the assumption that log $^{125}\text{I}/^{131}\text{I}$, etc. were normally distributed. The ratios were calculated on the basis of the percentage of the total amount of each isotope administered.

* The value differs from 1.00 at $P < 0.01$.

‡ The value differs from 1.00 at $P < 0.05$.

and reveal that the tissue distributions of ^{125}I and ^{57}Co were similar to each other 30 min after injection and that both isotopes were present in excess of ^{131}I at this time in all of the tissues studied. The significance of these results was confirmed by the statistical analysis (see Table I) of data obtained from five rabbits sacrificed 30 min after injection. Small but significant differences between the contents of ^{125}I and ^{57}Co were observed in the heart and lung. These differences could be due either to early release of ^{125}I from these organs or to insufficient adjustment for the decrease in counting efficiency for ^{125}I in these organs, since ^{125}I -labeled rabbit TCII might not have the same intraorgan distribution as the ^{125}I -labeled bovine serum albumin upon which the adjustments were based, as described under Methods. The net tissue uptake of ^{125}I and ^{57}Co at 30 min was actually somewhat greater than that shown in Fig. 3 and Table I, since all of the tissues were contaminated by plasma containing ^{131}I , present in approximately 20% excess of ^{125}I and ^{57}Co .

From 60 to 1,440 min after injection, the ratio of ^{57}Co to ^{131}I remained high in all of the tissues (see Fig. 3), but the ratios of ^{125}I to ^{131}I and ^{125}I to ^{57}Co decreased progressively and reached values of less than 0.1 by 1,440 min. The data in Fig. 3 also reveal that individual tissues varied markedly in their contents of ^{57}Co . When the amount of ^{57}Co present in the tissues at 1,440 min was corrected for the amount present in contaminating plasma and extracellular fluid (based on the ^{131}I content of individual tissues and the ratio of ^{57}Co to ^{131}I in plasma), the following values for the tissue contents of ^{57}Co , expressed as percent of administered ^{57}Co per gram of tissue, wet wt, were obtained: kidney, 1.29; liver, 0.192; spleen, 0.074; heart, 0.071; lung, 0.050; proximal small intestine, 0.079; middle small intestine, 0.076; and distal small intestine, 0.063. Values of 0.010 and less than < 0.005 were obtained for skeletal muscle and femoral bone marrow, respectively.

The high kidney content of ^{57}Co was not reduced when rabbits were subjected to bilateral ureteral ligation 60 min before the injection of rabbit TCII- ^{57}Co B $_{12}$. This observation suggests that glomerular filtration of TCII-B $_{12}$ is not involved in the process by which the kidney takes up TCII-B $_{12}$.

Additional experiments were performed in which ^{125}I -labeled rabbit TCII- ^{57}Co B $_{12}$ and ^{57}Co B $_{12}$ bound to unpurified TCII present in pooled rabbit serum were injected simultaneously into rabbits. The plasma and individual tissue contents of ^{57}Co and ^{65}Co differed from each other by less than 5% at 1, 4, and 24 h after injection. Several experiments were performed in which pentobarbital was omitted. The results obtained were indistinguishable from those in pentobarbital-treated rabbits.




FIGURE 4 Plasma survival and cumulative urinary excretion of ^{125}I , ^{57}Co , and ^{131}I , and the ratio of ^{131}I to ^{125}I in individual urine samples after the simultaneous intravenous injection of ^{125}I -labeled rabbit TCII- ^{57}Co B $_{12}$ and ^{131}I -labeled rabbit TCII devoid of B $_{12}$ into a rabbit. The experiment was performed as described in the legend to Fig. 2, except that the plasma volume was calculated with the assumption that 95.2% of the injected ^{57}Co B $_{12}$ was present in the plasma 5 min after its injection. The value of 95.2% is the average value obtained for ^{57}Co in 16 experiments in which ^{125}I -labeled rabbit TCII- ^{57}Co B $_{12}$ was injected simultaneously with ^{131}I -labeled bovine serum albumin.

Plasma survival and tissue distribution of apo- and holo-rabbit TCII. When ^{131}I -labeled rabbit TCII devoid of B $_{12}$ was mixed with ^{125}I -labeled rabbit TCII- ^{57}Co B $_{12}$ and injected intravenously into a rabbit, the ^{131}I disappeared from the plasma 30% faster than the ^{125}I , and more ^{131}I than ^{125}I was excreted in the urine during the 240-min course of the experiment, as shown in Fig. 4. When the ^{131}I -labeled rabbit TCII was saturated with unradioactive B $_{12}$ before this experiment was repeated, the plasma survivals and urinary excretions of ^{125}I and ^{131}I were no longer distinguishable from each other (data not presented). All of the urinary ^{125}I and ^{131}I in these experiments had an apparent mol wt of less than 1,000 based on gel filtration.

Data concerning the tissue distributions of ^{131}I , ^{125}I , and ^{57}Co 30 min after the simultaneous intravenous injection of ^{131}I -labeled rabbit TCII and ^{125}I -labeled rabbit TCII- ^{57}Co B $_{12}$ are presented in Table II. The failure to find marked differences in the ratio of ^{125}I to ^{131}I in the tis-

TABLE II
Relative Tissue Distribution of ^{125}I , ^{131}I , and ^{57}Co , 30 min after the Simultaneous Intravenous Injection of ^{125}I -Labeled Rabbit TCII- ^{57}Co B $_{12}$ and ^{131}I -Labeled Rabbit TCII into Rabbits

Organ	$^{125}\text{I}/^{131}\text{I}$		$^{57}\text{Co}/^{131}\text{I}$		$^{125}\text{I}/^{57}\text{Co}$	
	Range	Mean	Range	Mean	Range	Mean
Plasma	1.07–1.15	1.13*	1.05–1.20	1.14*	0.96–1.02	0.99
Liver	0.92–1.09	0.99	0.94–1.13	1.07	0.89–1.00	0.94
Kidney	0.80–0.91	0.84*	0.75–0.96	0.81*	0.95–1.07	1.03
Spleen	0.85–1.23	1.02	0.86–1.29	1.04	0.96–1.01	0.98
Heart	1.13–1.22	1.17*	1.31–1.43	1.39*	0.83–0.86	0.84*
Lung	1.09–1.17	1.12*	1.10–1.30	1.20*	0.90–0.99	0.94†
Small intestine						
Proximal	0.91–1.05	1.01	0.92–1.02	0.97	0.98–1.09	1.04
Middle	0.98–1.08	1.04	1.01–1.32	1.11	0.81–1.01	0.94
Distal	0.98–1.15	1.05	1.03–1.24	1.11†	0.86–1.10	0.96

Five rabbits were injected. Statistical analysis employed the Student *t* test and was based on the assumption that $\log ^{125}\text{I}/^{131}\text{I}$, etc. were normally distributed. The ratios were calculated on the basis of the percent of the total amount of each isotope administered.

* The value differs from 1.00 at $P < 0.01$.

† The value differs from 1.00 at $P < 0.05$.

sues examined indicates that apo- and holo-rabbit TCII are taken up by tissues similarly, although not identically.

The experiments in this section suggested that the ^{125}I moiety of ^{125}I -labeled rabbit TCII- ^{57}Co B $_{12}$ might be converted to its low-mol-wt form only after the release of ^{57}Co B $_{12}$ to tissues, and only if the ^{125}I -labeled rabbit TCII fails to bind another molecule of B $_{12}$ in the plasma. This possibility was tested by injecting 5 mg of B $_{12}$ intravenously immediately before the injection of ^{125}I -labeled rabbit TCII- ^{57}Co B $_{12}$, and subsequently maintaining a continuous infusion of unradioactive B $_{12}$ at a rate of 5 $\mu\text{g}/\text{min}$. This possibility appears unlikely, since under these conditions of continuous saturation of TCII with B $_{12}$, the ^{125}I was cleared rapidly from the plasma at its usual rate and 45% of the ^{125}I was excreted in the urine during the 240-min course of the experiment.

Comparison of rabbit TCII and human TCII. When ^{125}I -labeled human TCII- ^{57}Co B $_{12}$ was mixed with ^{131}I -labeled rabbit TCII-B $_{12}$ and injected intravenously into a rabbit, the ^{125}I was cleared from the plasma and excreted in the urine faster than the ^{131}I , as shown in Fig. 5. When ^{125}I -labeled human TCII- ^{57}Co B $_{12}$ was mixed with native rabbit TCII- ^{57}Co B $_{12}$ and injected intravenously into a rabbit, ^{57}Co was cleared from the plasma faster than ^{58}Co , as shown in Fig. 6. The rabbit utilized for this experiment was sacrificed 240 min after the injection, and the tissue distributions of ^{57}Co and ^{58}Co were determined. The data are presented in Table III and reveal marked differences in the ratio of ^{57}Co to ^{58}Co in individual tissues. This observation suggests that individual tissues may vary in the degree with which they take up B $_{12}$ bound to human and rabbit TCII. No firm

conclusions can be reached in this regard, however, since some or all of the differences in the ratio of ^{57}Co to ^{58}Co could be due to differences in the recirculation of ^{57}Co and ^{58}Co or to differences in tissue contamination with plasma and extracellular fluid.

When ^{57}Co B $_{12}$ bound to partially purified human TCII (obtained by incubating ^{57}Co B $_{12}$ with human serum and isolating TCII- ^{57}Co B $_{12}$ by gel filtration) was mixed with ^{58}Co B $_{12}$ bound to similarly partially purified rabbit TCII and injected, the ^{57}Co B $_{12}$ was also cleared more rapidly than the ^{58}Co B $_{12}$, thus indicating that the purification and labeling of the TCII molecule was not the cause of the differences observed between human TCII-B $_{12}$ and rabbit TCII-B $_{12}$. This view is also supported by experiments that demonstrated (data not presented) that ^{58}Co B $_{12}$ bound to partially purified human TCII was cleared from rabbit plasma by tissues in a manner indistinguishable from simultaneously injected ^{57}Co B $_{12}$ bound to ^{125}I -labeled human TCII. Tissue distribution data were obtained 1, 4, and 24 h after injection. When ^{125}I -labeled human TCII- ^{57}Co B $_{12}$ was incubated with rabbit plasma for 4 h at 37°C, more than 90% of the ^{125}I and ^{57}Co eluted from Sephadex G-150 with an apparent mol wt of approximately 38,000 and were adsorbed by rabbit anti-human TCII-Sepharose. This indicates that human TCII was not degraded and that B $_{12}$ bound to human TCII did not exchange markedly with rabbit TCII under these conditions.

Plasma survival of apo- and holo-human TCII. When ^{125}I -labeled human TCII- ^{57}Co B $_{12}$ was mixed with ^{131}I -labeled human TCII and injected intravenously into a

rabbit, the ^{125}I was cleared from the plasma approximately 30% faster than the ^{125}I , as shown in Fig. 7. The urinary excretion of ^{125}I also proceeded faster than that of ^{125}I . All of the ^{125}I and ^{125}I in the urine had an apparent mol wt of less than 1,000, based on gel filtration.

Plasma survival of human TCII as determined by radioimmunoassay. Purified but unlabeled human TCII- B_{12} (24 μg of protein and 0.74 μg of B_{12}) was mixed with ^{125}I -labeled bovine serum albumin and injected intravenously into a rabbit. The amount of TCII- B_{12} injected increased the rabbit's total plasma TCII- B_{12} concentration by approximately 15%. The content of human TCII in plasma samples obtained from 5 to 1,440 min after injection was assayed by a radioimmunoassay specific for human TCII, as compared with rabbit TCII, since the antiserum was raised in rabbits. The plasma survival data are presented in Fig. 8 and reveal that the plasma survival of unlabeled human TCII based on the




FIGURE 5 Plasma survival and cumulative urinary excretion of ^{125}I , ^{57}Co , and ^{131}I and the ratio of ^{125}I to ^{131}I in individual urine samples after the simultaneous intravenous injection of ^{125}I -labeled human TCII- $[\text{Co}]\text{B}_{12}$ and ^{125}I -labeled rabbit TCII- B_{12} into a rabbit. The experiment was performed as described in the legend to Fig. 2, except that the plasma volume was calculated on the assumption that 94.7% of the injected ^{125}I was present in the plasma 5 min after its injection. The value of 94.7% is the average value observed for ^{125}I in 16 experiments in which ^{125}I -labeled rabbit TCII- $[\text{Co}]\text{B}_{12}$ was injected simultaneously with ^{125}I -labeled bovine serum albumin.




FIGURE 6 Plasma survival of ^{125}I , ^{57}Co , and ^{58}Co after the simultaneous intravenous injection of ^{125}I -labeled human TCII- $[\text{Co}]\text{B}_{12}$ and unlabeled rabbit TCII- $[\text{Co}]\text{B}_{12}$. The experiment was performed as described in the legends to Figs. 2 and 4. The injected unlabeled rabbit TCII- $[\text{Co}]\text{B}_{12}$ (25 ng B_{12}) was prepared by incubating a 1.1-fold excess of $[\text{Co}]\text{B}_{12}$ with 5.8 ml of pooled rabbit serum at 4°C for 45 min and subsequently subjecting the sample to gel filtration on Sephadex G-150 as described in the legend to Fig. 1.

radioimmunoassay was essentially the same as that determined with ^{125}I -labeled human TCII (compare Fig. 8 with Figs. 5, 6, and 7). The same result was obtained when this experiment was repeated with a second rabbit. These observations are consistent with the concept that TCII is degraded after its uptake by tissues and make it extremely unlikely that the small-mol-wt ^{125}I -material is formed by mere elution of the ^{125}I from the TCII molecule.

DISCUSSION

The studies presented here demonstrate that rabbit and human TCII can be covalently labeled with ^{125}I - or ^{125}I -

TABLE III
Tissue Distribution of ^{125}I , ^{57}Co , and ^{58}Co 240 min after the Simultaneous Intravenous Injection of ^{125}I -Labeled Human TCII- $[\text{Co}]\text{B}_{12}$ and Rabbit TCII- $[\text{Co}]\text{B}_{12}$

Organ	^{125}I	^{57}Co	^{58}Co	$^{57}\text{Co}/^{58}\text{Co}$
Plasma	3.18	15.2	20.9	0.73
Liver	1.17	15.8	11.3	1.39
Kidney	2.12	24.1	13.4	1.80
Spleen	0.008	0.105	0.102	1.03
Heart	0.081	0.571	0.535	1.07
Lung	0.186	0.980	1.020	0.96
Small intestine				
Proximal	0.186	1.32	1.48	0.90
Middle	0.217	1.21	1.27	0.95
Distal	0.377	1.54	1.58	0.97

Values were obtained from a single experiment.




FIGURE 7 Plasma survival and cumulative urinary excretion of ^{125}I , ^{57}Co , and ^{131}I and the ratio of ^{131}I to ^{125}I in individual urine samples after the simultaneous intravenous injection of ^{125}I -labeled human TCII- ^{57}Co B_{12} and ^{131}I -labeled human TCII devoid of B_{12} into a rabbit. The experiment was performed as described in the legend to Fig. 2, except that the plasma volume was calculated on the assumption that 82% of the ^{57}Co B_{12} was present in the plasma 5 min after its injection. The value of 82% was the value observed in the experiment shown in Fig. 5.

labeled *N*-succinimidyl-3-(4-hydroxyphenyl) propionate without causing significant alterations in the biological activities of these proteins. The labeled proteins retain their ability to bind B_{12} , since the apo-proteins are adsorbed (more than 90%) by B_{12} -Sephadex, while the holo-proteins are not adsorbed (less than 10%) by B_{12} -Sephadex. The labeled proteins also retain their ability to transport B_{12} in vivo, since B_{12} bound to the labeled proteins is cleared from rabbit plasma by tissues in a manner indistinguishable from that of B_{12} bound to the unlabeled native proteins. In the case of human TCII, it has also been possible to demonstrate that the plasma survival in rabbits of ^{125}I -labeled human TCII- B_{12} , based on the survival of the ^{125}I moiety, is indistinguishable from the survival of unlabeled human TCII- B_{12} , determined by a radioimmunoassay specific for human TCII, as opposed to rabbit TCII, since the anti-human TCII antibodies employed in the assay were raised in rabbits.

The availability of functional TCII- B_{12} containing a covalently bound radioactive label on the protein moiety, in addition to a different radioactive label in the B_{12}

moiety, has enabled us to elucidate the role and fate of TCII in the plasma transport of B_{12} . The experiments employing ^{125}I -labeled rabbit TCII- ^{57}Co B_{12} indicate that the entire TCII- B_{12} complex is cleared from rabbit plasma by a large number of tissues that include the kidney, liver, heart, lung, and spleen and the proximal, middle, and distal portions of the small intestine. The TCII moiety appears to be degraded during this process since 30 min after the intravenous injection of ^{125}I -labeled rabbit TCII- ^{57}Co B_{12} , the ratio of ^{125}I to ^{57}Co decreases progressively in all of the tissues studied and a form of ^{125}I with a mol wt of less than 1,000 appears in the plasma and is rapidly excreted in the urine. That ^{125}I does not accumulate in excess of ^{57}Co B_{12} in any of the tissues studied suggests that the TCII moiety is degraded at the site of the initial tissue uptake of the TCII- B_{12} complex. These observations indicate that the TCII-facilitated transport of B_{12} differs considerably from the transferrin-facilitated transport of iron, since although transferrin transports iron rapidly to tissues ($t_{1/2}$ of plasma survival of iron = 60–90 min), the transferrin moiety has a prolonged plasma survival of 8–10 days (26).

The ^{57}Co B_{12} moiety of ^{125}I -labeled rabbit TCII- ^{57}Co B_{12} is cleared from rabbit plasma at the same rate as the ^{125}I -labeled rabbit TCII moiety during the first




FIGURE 8 Plasma survival of ^{131}I and immunologic human TCII after the simultaneous intravenous injection of ^{131}I -labeled bovine serum albumin and unlabeled human TCII- B_{12} into a rabbit. The experiment was performed as described in the legend to Fig. 2. The injected sample contained homogeneous unlabeled human TCII saturated with 740 ng of bound B_{12} . Plasma samples were assayed for human TCII by a radioimmunoassay as described under Methods.

60 min after the intravenous injection of the complex, but at subsequent time periods the plasma ratio of [^{57}Co]B₁₂ to ^{125}I -labeled TCII increases progressively. This observation suggests that a significant portion of the B₁₂ reenters the plasma after its initial uptake by tissues. This phenomenon could explain the discrepancy between the rapid early and the slow late clearance of TCII-[^{57}Co]B₁₂ from human plasma (see Introduction), although it should be emphasized that conclusions based on observations made in rabbits may not necessarily be valid for other species. It is also important to note that cyanocobalamin was employed in our studies, since different results might be found with hydroxo-, methyl-, or 5'deoxyadenosyl cobalamins.

Recent studies (13) employing ^{125}I -labeled human granulocyte B₁₂-binding protein-[^{57}Co]B₁₂, ^{125}I -labeled human TCIII-[^{57}Co]B₁₂, and ^{125}I -labeled desialylated human TCI-[^{57}Co]B₁₂ have demonstrated that these glycoprotein-B₁₂ complexes are cleared rapidly from rabbit plasma ($t_{1/2}$ less than 5 min) exclusively by the liver. Hepatic uptake is effected by the mechanism elucidated by Ashwell and Morell (14), in which glycoproteins containing terminal galactose residues bind to hepatocyte plasma membrane receptors, enter cells in intact form, presumably by pinocytosis, and are subsequently degraded by lysosomal enzymes. In the case of ^{125}I -labeled B₁₂-binding protein [^{57}Co]B₁₂ complexes mentioned above, the ^{125}I reappears in the plasma in low-mol-wt (less than 1,000) form 30 min after hepatic uptake and is rapidly excreted in the urine, while 70-80% of the ^{57}Co reenters the plasma from 60 to 180 min after uptake and is present bound to rabbit TCII. The similarity between the kinetics of these phenomena and those observed with ^{125}I -labeled TCII-[^{57}Co]B₁₂ suggests that the entire TCII-B₁₂ complex may be taken up by a variety of cells by pinocytosis and that the TCII moiety may be degraded subsequently by lysosomal enzymes. Evidence in support of this possibility has been obtained by Pletsch and Coffey (27, 28) in studies that involved the subcellular fractionation of rat liver at various times after the intravenous injection of [^{57}Co]B₁₂ bound rapidly in vivo by rat plasma TCII. The availability of ^{125}I -labeled TCII should enhance future studies of this kind.

The rapid turnover of TCII appears to place an unnecessary metabolic burden on the body, although it is important to note that this burden is relatively minor, since TCII accounts for only 0.0025% and 0.00005% of the total protein present in rabbit and human plasma, respectively. It is possible that TCII must be degraded to free the tightly bound B₁₂ molecule (affinity constant = 10^{11}M^{-1} [29]) for intracellular use, although protein degradation is not involved in the cellular uptake of iron from transferrin, despite the fact that the affinity constant for iron and transferrin is of the order of 10^{21}M^{-1}

(30). This explanation also appears unlikely since it would not account for the fact that apo-TCII is cleared from plasma and degraded actually slightly faster than holo-TCII. Rapid turnover of TCII, together with rapid recirculation of B₁₂, could be advantageous, in that it could be utilized as part of a mechanism to effect rapid changes in the amount of B₁₂ delivered to cells within the body.

ACKNOWLEDGMENTS

This work was supported by Grants AM 16668 and AM 05089 from the National Institutes of Health.

REFERENCES

- Schneider, R. J., C. S. Mehlmán, and R. H. Allen. 1974. The role of transcobalamin II in the plasma transport of vitamin B₁₂. *Blood*. **44**: 910. (Abstr.).
- Scott, J. M., F. J. Bloomfield, R. Stebbins, and V. Herbert. 1974. Studies on the derivation of transcobalamin III from granulocytes. Enhancement by lithium and elimination by fluoride of in vitro increments in vitamin B₁₂-binding capacity. *J. Clin. Invest.* **53**: 228-239.
- Gräsbeck, R. 1969. Intrinsic factor and other vitamin B₁₂ transport proteins. *Prog. Hematol.* **6**: 233-260.
- Hall, C. A., and A. E. Finkler. 1971. Isolation and evaluation of the various B₁₂ binding proteins in human plasma. *Methods Enzymol.* **18**(Part C): 108-126.
- Allen, R. H., and P. W. Majerus. 1972. Isolation of vitamin B₁₂ binding proteins using affinity chromatography. III. Purification and properties of human plasma transcobalamin II. *J. Biol. Chem.* **247**: 7709-7717.
- Burger, R. L., C. S. Mehlmán, and R. H. Allen. 1975. Human plasma R-type vitamin B₁₂ binding proteins. I. Isolation and characterization of transcobalamin I, transcobalamin III, and the normal granulocyte vitamin B₁₂ binding protein. *J. Biol. Chem.* **250**: 7700-7706.
- Allen, R. H., and P. W. Majerus. 1972. Isolation of vitamin B₁₂ binding proteins using affinity chromatography. II. Purification and properties of a human granulocyte vitamin B₁₂ binding protein. *J. Biol. Chem.* **247**: 7702-7708.
- Burger, R. L., and R. H. Allen. 1974. Characterization of vitamin B₁₂-binding proteins isolated from human milk and saliva by affinity chromatography. *J. Biol. Chem.* **249**: 7220-7227.
- Burger, R. L., S. Waxman, H. S. Gilbert, C. S. Mehlmán, and R. H. Allen. 1975. Isolation and characterization of a novel vitamin B₁₂-binding protein associated with hepatocellular carcinoma. *J. Clin. Invest.* **56**: 1262-1270.
- Stenman, U.-H. 1974. Amniotic fluid vitamin B₁₂-binding protein. Purification and characterization with isoelectric focusing and other techniques. *Biochim. Biophys. Acta.* **263**: 173-184.
- Benson, R. E., M. E. Rappazzo, and C. A. Hall. 1972. Late transport of vitamin B₁₂ by transcobalamin II. *J. Lab. Clin. Med.* **80**: 488-495.
- Hom, B. L., and H. A. Olesen. 1969. Plasma clearance of ^{57}Co -labelled vitamin B₁₂ bound in vitro and in vivo to transcobalamin I and II. *Scand. J. Clin. Lab. Invest.* **23**: 201-211.
- Burger, R. L., R. J. Schneider, C. S. Mehlmán, and R. H. Allen. 1975. Human plasma R-type vitamin B₁₂ binding proteins. II. The role of transcobalamin I, trans-

- cobalamin III, and the normal granulocyte vitamin B₁₂ binding protein in the plasma transport of vitamin B₁₂. *J. Biol. Chem.* **250**: 7707-7713.
14. Ashwell, G., and A. G. Morell. 1974. The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. *Adv. Enzymol.* **41**: 99-128.
 15. Carmel, R., and V. Herbert. 1969. Deficiency of vitamin B₁₂-binding alpha globulin in two brothers. *Blood.* **33**: 1-12.
 16. Cooper, B. A., and W. Paranchych. 1961. Selective uptake of specifically bound cobalt-58 vitamin B₁₂ by human and mouse tumor cells. *Nature (Lond.)*. **191**: 393-395.
 17. Retief, F. R., C. W. Gottlieb, and V. Herbert. 1966. Mechanism of vitamin B₁₂ uptake by erythrocytes. *J. Clin. Invest.* **45**: 1907-1915.
 18. Finkler, A. E., and C. A. Hall. 1967. Nature of the relationship between vitamin B₁₂ binding and cell uptake. *Arch. Biochem. Biophys.* **120**: 79-85.
 19. Ryel, E. M., L. M. Meyer, and R. A. Gams. 1974. Uptake and subcellular distribution of vitamin B₁₂ in Mouse L1210 leukemic lymphoblasts. *Blood.* **44**: 427-433.
 20. Rosenberg, L. E., A. Lilljequist, and R. H. Allen. 1973. Transcobalamin II-facilitated uptake of vitamin B₁₂ by cultured fibroblasts: studies in methylmalonicaciduria. *J. Clin. Invest.* **52**: 69a-70a. (Abstr.).
 21. Hakami, N., P. E. Neiman, G. P. Cannellos, and J. Lazerson. 1970. Neonatal megaloblastic anemia due to inherited transcobalamin II deficiency in two siblings. *N. Engl. J. Med.* **285**: 1163-1170.
 22. Hall, C. A., and A. E. Finkler. 1965. The dynamics of transcobalamin II. A vitamin B₁₂ binding substance in plasma. *J. Lab. Clin. Med.* **65**: 459-468.
 23. Bolton, A. E., and W. M. Hunter. 1973. The labelling of proteins to high specific radioactivities by conjugation to a ¹²⁵I-containing acylating agent. Application to the radioimmunoassay. *Biochem. J.* **133**: 529-539.
 24. Allen, R. H., and C. S. Mehlman. 1973. Isolation of gastric vitamin B₁₂ binding proteins using affinity chromatography. I. Purification and properties of human intrinsic factor. *J. Biol. Chem.* **248**: 3660-3669.
 25. Allen, R. H., and P. W. Majerus. 1972. Isolation of vitamin B₁₂-binding proteins using affinity chromatography. I. Preparation and properties of vitamin B₁₂-Sephacrose. *J. Biol. Chem.* **247**: 7695-7701.
 26. Awai, M., and E. B. Brown. 1963. Studies of the metabolism of I¹²⁵-labeled human transferrin. *J. Lab. Clin. Med.* **61**: 363-396.
 27. Pletsch, Q. A., and J. W. Coffey. 1971. Intracellular distribution of radioactive vitamin B₁₂ in rat liver. *J. Biol. Chem.* **246**: 4619-4629.
 28. Pletsch, Q. A., and J. W. Coffey. 1972. Properties of the proteins that bind vitamin B₁₂ in subcellular fractions of rat liver. *Arch. Biochem. Biophys.* **151**: 157-167.
 29. Hippe, E., and H. Olesen. 1971. Nature of vitamin B₁₂ binding. III. Thermodynamics of binding to human intrinsic factor and transcobalamins. *Biochim. Biophys. Acta.* **243**: 83-89.
 30. Aasa, R., B. G. Malmström, P. Saltman, and T. Vänngård. 1963. The specific binding of iron (III) and copper (II) to transferrin and conalbumin. *Biochim. Biophys. Acta.* **75**: 203-222.